Adults w/ insufficiently controlled type 2 DM as an adjunct to diet & exercise: As monotherapy when metformin is considered inappropriate due to intolerance or contraindications; or in addition to other medicinal products for the treatment of diabetes.
SC (abdomen, thigh or upper arm)Monotherapy 0.75 mg once wkly. Add-on therapy 1.5 mg once wkly. Potentially vulnerable population Starting dose: 0.75 mg once wkly.
Not to be administered IV or IM. Not to be used in patients w/ type 1 DM or for the treatment of diabetic ketoacidosis. Not a substitute for insulin. Potential risk of dehydration, particularly in relation to GI adverse reactions; avoid fluid depletion. Not recommended in patients w/ severe GI disease, including severe gastroparesis; ESRD (<15 mL/min/1.73 m2). Discontinue if acute pancreatitis is suspected. Increased risk of hypoglycemia in combination w/ sulphonylurea or insulin. Advise patients to take precautions avoiding hypoglycemia while driving & using machines. Not recommended during pregnancy. Not to be used during lactation. Safety & efficacy in childn <18 yr have not yet been established.
Delayed gastric emptying & has potential to impact rate of absorption of oral medicinal products. Potential for altered exposure to patients in combination w/ oral medicinal products w/ rapid GI absorption or PR formulation. Increased exposure w/ sitagliptin may enhance effects on blood glucose levels.
Sign Out
